- In combination with other ARV agents for treating HIV-1 infection in treatment-experienced pts with PIs-, NRTIs-, and NNRTI-resistant variants.
- Treatment-experienced HIV-infected pediatric patients (6 -18 years of age and weighing at least 16 kg).
NON-FDA APPROVED USES
- Potential for use in first-line therapy for pts infected with NNRTI-resistant virus (untested)
There's more to see -- the rest of this topic is available only to subscribers.